|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intravenous immune globulin suppresses angiogenesis in mice and humans显示文摘Human intravenous immune globulin(IVIg),a purified IgG fraction composed of~60%IgG1 and obtained from the pooled plasma of thousands of donors,is clinically used for a wide range of diseases.The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG(IgG)Fc regions.Recently,we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI,a high-affinity receptor for IgG1.Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases,namely,neovascular age-related macular degeneration,corneal neovascularization,colorectal cancer,fibrosarcoma and peripheral arterial ischemic disease.Angioinhibition was mediated by the Fc region of IVIg,required FcγRI and had similar potency in transgenic mice expressing human FcγRs.Finally,IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities.These data place IVIg,an agent approved by the US Food and Drug Administration,as a novel angioinhibitory drug in doses that are currently administered in the clinical setting.In addition,they raise the possibility of an unintended effect of IVIg on blood vessels. | Reo Yasuma Valeria Cicatiello Takeshi Mizutani Laura Tudisco Younghee Kim Valeria Tarallo Sasha Bogdanovich Yoshio Hirano Nagaraj Kerur Shengjian Li Tetsuhiro Yasuma Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Balamurali K Ambati Sevim Barbasso Helmers Ingrid E Lundberg Ondrej Viklicky Jeanette HW Leusen J Sjef Verbeek Bradley D Gelfand Ana Bastos-Carvalho Sandro De Falco Jayakrishna Ambati | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 3 |
| 2 | Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection显示文摘AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1.METHODS: The sustained virological response(SVR) rate, IL28 B genotype, IFNL4 genotype, initial viral load(IVL) and other pretreatment variables in 39 endstage renal disease patients(ESRD) on maintenance haemodialysis(HD) infected with hepatitis C virus(HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment nave and had well compensated liver disease. The ESRD patients received 135 μg of PEGylated interferon α-2a(Peg IFN-α) weekly and a reduced dose of ribavirin(RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/d L. Control group patients were given standard doses of Peg IFN-α and RBV. SVR was assessed as HCV RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for comparisons of the means and a χ2 testcompared the frequencies.Logistic regression was used to determine significant predictors of SVR.Cutoff values for continuous variables were obtained from Receiver Operating Characteristic analysis.RESULTS:The distribution of IL28B rs12979860 CC,CT and TT genotypes in the ESRD group was 28.2%,64.1%and 7.7%,respectively,and 19.3%,62.4%and18.3%in the controls.The IFNL4 genotype was in almost absolute linkage disequlibrium with IL28B.The proportion of patients with a low IVL(<600000 IU/m L)was significantly higher in the ESRD group than in the controls(28/39,71.8%vs 51/109,46.8%,P=0.009),as was the proportion of patients with low IVL in IL28B CC carriers compared with non-CC carriers in the ESRD group(10/11,90.9%vs 18/28,64.3%,P=0.0035).This difference was not found in the controls(7/22,31.8%vs 44/87,50.6%,P=0.9).The overall SVR rate was 64.1%(25/39)in the ESRD group and 50.5%(55/109)in the control group(P=0.19).11/11(100%)and 19/22(86.4%)IL28B CC patients achieved SVR in the ESRD and control groups,respectively.A statistically significant association between SVR and IL28B and IFNL4 variants was found in both groups.The ESRD patients who achieved SVR showed the lowest IVL[median 21000,interquartile range(IQR):6000-23000IU/m L],compared with ESRD individuals without SVR(1680000,IQR:481000-6880000,P=0.001),controls with SVR(387000,IQR:111000-1253000)and controls without SVR(905000,IQR:451000-3020000).In ESRD,an IVL<600000 IU/m L was strongly associated with SVR:24/28(85.7%)patients who achieved SVR had viraemia below this threshold.CONCLUSION:Haemodialysis decreases the viral load,especially in IL28B CC genotype carriers.A low IVL was the strongest predictor of SVR in ESRD patients identified in multivariate analysis. | Jan Sperl Sona Frankova Renata Senkerikova Magdalena Neroldova Vaclav Hejda Miroslava Volfova Dusan Merta Ondrej Viklicky Julius Spicak Milan Jirsa | 2015 | World Journal of Gastroenterology2015，21，18： | 2 |
| 3 | Expression of class III β-tubulin in normal and neoplastic human tissues显示文摘 | E. Dráberová Zdenek Lukás Dagmar Ivanyi Vladimír Viklicky Pavel Dráber | 1998 | Histochemistry and Cell Biology1998，，3： | 1 |
| 4 | Expression of class Ⅲ beta-tubulin in neuroendocrine tumours of gastrointestinal tract显示文摘 | Jirasek T Mandys V Viklicky V | 2002 | Folia Histochem Cytobiol2002，40，3： | 1 |
| 5 | Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen显示文摘 | BUBENiK 3 BARESOV/k M VIKLICKY V | 1973 | Int J Cancer1973，11，3： | 1 |
| 6 | B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients显示文摘 | Viklicky O Krystufkova E Brabcova I | 2013 | Transplantation2013，95，1： | 1 |
| 7 | SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts.显示文摘 | Viklicky O Zou H Muller V | | 0，，： | 1 |
| 8 | TGF-betal expression and chronic allograft nephropathy in protocol Kidney graft biopsy 显示文摘 | Viklicky O Matl I Voska L | 2003 | Physiol Res2003，52，3： | 1 |
| 9 | TGF-betal expression and chronic allograft nephropathy in protocol kidney graft biopsy 显示文摘 | Viklicky O Matl I Voska L | 2003 | Physiol Res2003，52，3： | 1 |
| 10 | New immonosuppressive agents in chronic progressive glomerulopathies an update 显示文摘 | Bloudickova S Viklicky O | 2004 | Prague Med Rep2004，105，3： | 1 |
| 11 | Associa- tion between heat shock protein 70s and Toll-like receptor polymorphisms with long-term renal allo-graft survival 显示文摘 | Fekete A Viklicky O Hubacek JA | 2006 | Transpl Int2006，19，3： | 1 |
| 12 | Association between heat shock protein 70s and toll-like receptor polymorphisms with longterm renal allograft survival显示文摘 | Fekete A Viklicky O Hubacek JA | 2006 | Transpl Int2006，19，3： | 1 |
| 13 | TGF-betal expression and chronic allograft nephropathy in protocol kidney graft biopsy显示文摘 | Viklicky O Matl I Voska L | 2003 | Physiol Res2003，52，3： | 1 |
| 14 | Expression of class Ⅲ beta-tubulin in neuroendocrine tumours of gastrointestinal tract显示文摘 | Mandys V Viklicky V | 2002 | Folia Histochem Cytobiol2002，40，3： | 1 |
| 15 | SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts 显示文摘 | Viklicky O Zou H Muller V | 2000 | Transplantation2000，69，4： | 1 |
| 16 | Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival 显示文摘 | Fekete A Viklicky 0 Hub6cek J A | 2006 | Transpl Int2006，19，3： | 1 |
| 17 | The incidence ofinfectious diseases after renal transplantation:a single-centre expe-rience显示文摘 | Lyerova L Viklicky O Nemcova D Teplan V | 2008 | Int J Antimicrob Agents2008，31，1： | 1 |
| 18 | Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation显示文摘 | Seiler M Brabcova I Viklicky O | 2007 | Am J Transplant2007，7，2： | 1 |
| 19 | New immunosuppressive agents in chronic progressive glomerulopathies:an update显示文摘 | Bloudickova S Viklicky O | 2004 | Prague Med Rep2004，105，3： | 1 |
| 20 | Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation 显示文摘 | Seller M Brabcova I Viklicky O | 2007 | Am J Transplant2007，7，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员